Externally Led - Patient Driven Drug Development (EL-PFDD)

Patient lived experience will convey the importance and urgency of new therapies to the Food & Drug Administration (FDA), researchers, pharma, healthcare providers, and federal regulators, leveraging the unique power of patient experience.

This meeting is hosted by the Hypertrophic Cardiomyopathy Association in partnership with the Danon Foundation, FARA, the DCM Foundation, SADS Foundation, and ARC. It’s an important opportunity to help inform how the FDA considers treatments for genetic cardiomyopathies.